Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature

被引：52

作者：

Noronha, Vanita

Berliner, Nancy

Ballen, Karen K.

Lacy, Jill

Kracher, Jean

Baehring, Joachim

Henson, John W.

机构：

[1] Massachusetts Gen Hosp, Pappas Ctr Neurooncol, Boston, MA 02114 USA

[2] Yale Univ, Sch Med, Dept Med, Div Med Oncol, New Haven, CT 06510 USA

[3] Yale Univ, Sch Med, Yale Brain Tumor Ctr, Dept Neurol, New Haven, CT 06510 USA

[4] Yale Univ, Sch Med, Yale Brain Tumor Ctr, Dept Neurosurg, New Haven, CT 06510 USA

[5] Massachusetts Gen Hosp, Dept Med, Div Hematol, Boston, MA 02114 USA

[6] Harvard Univ, Sch Med, Boston, MA 02115 USA

来源：

NEURO-ONCOLOGY | 2006年 / 8卷 / 03期

关键词：

brain neoplasm; glioblastoma; myelodysplastic syndrome; recurrent glioma; secondary leukemia; secondary myelodysplastic syndrome; temozolomide; treatment complication;

D O I：

10.1215/15228517-2006-003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The emergence of temozolomide as an effective alkylating agent with little acute toxicity or cumulative myelosuppression has led to protracted courses of chemotherapy for many patients with gliomas. Secondary, or treatment-related, myelodysplasia (t-MDS) and acute myelogenous leukemia (t-AML) are life-threatening complications of alkylating chemotherapy and have been reported in patients with primary brain tumors. We describe a case of temozolomide-related t-MDS/AML and discuss the clinical features of this condition. Administration of an alkylating agent in patient populations with long median survivals must be undertaken with an understanding of the potential for this treatment complication.

引用

页码：280 / 283

页数：4

共 15 条

[1]

New trends in umbilical cord blood transplantation [J].